Discovery of TDI-10229: A Potent and Orally Bioavailable Inhibitor of Soluble Adenylyl Cyclase (sAC, ADCY10).

Saved in:
Bibliographic Details
Title: Discovery of TDI-10229: A Potent and Orally Bioavailable Inhibitor of Soluble Adenylyl Cyclase (sAC, ADCY10).
Authors: Fushimi M; Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States., Buck H; Department of Pharmacology, Weill Cornell Medicine, New York, New York 10021, United States., Balbach M; Department of Pharmacology, Weill Cornell Medicine, New York, New York 10021, United States., Gorovyy A; Department of Pharmacology, Weill Cornell Medicine, New York, New York 10021, United States., Ferreira J; Department of Pharmacology, Weill Cornell Medicine, New York, New York 10021, United States., Rossetti T; Department of Pharmacology, Weill Cornell Medicine, New York, New York 10021, United States., Kaur N; Department of Pharmacology, Weill Cornell Medicine, New York, New York 10021, United States., Levin LR; Department of Pharmacology, Weill Cornell Medicine, New York, New York 10021, United States., Buck J; Department of Pharmacology, Weill Cornell Medicine, New York, New York 10021, United States., Quast J; Department of Biochemistry, University of Bayreuth, 95440 Bayreuth, Germany., van den Heuvel J; Helmholtz-Zentrum für Infektionsforschung, 38124 Braunschweig, Germany., Steegborn C; Department of Biochemistry, University of Bayreuth, 95440 Bayreuth, Germany., Finkin-Groner E; Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States., Kargman S; Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States., Michino M; Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States., Foley MA; Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States., Miller M; Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States., Liverton NJ; Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States., Huggins DJ; Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York 10021, United States., Meinke PT; Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.; Department of Pharmacology, Weill Cornell Medicine, New York, New York 10021, United States.
Source: ACS medicinal chemistry letters [ACS Med Chem Lett] 2021 Jul 14; Vol. 12 (8), pp. 1283-1287. Date of Electronic Publication: 2021 Jul 14 (Print Publication: 2021).
Publication Type: Journal Article
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101521073 Publication Model: eCollection Cited Medium: Print ISSN: 1948-5875 (Print) Linking ISSN: 19485875 NLM ISO Abbreviation: ACS Med Chem Lett Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1948-5875
DOI:10.1021/acsmedchemlett.1c00273